<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9162">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02987660</url>
  </required_header>
  <id_info>
    <org_study_id>RFL605-P001</org_study_id>
    <nct_id>NCT02987660</nct_id>
  </id_info>
  <brief_title>Comparison of Topography Guided LASIK With WaveLight® EX500 to SMILE With Zeiss VisuMax</brief_title>
  <official_title>Comparison of Topography Guided LASIK With WaveLight® EX500 to SMILE With Zeiss VisuMax</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon, a Novartis Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare Topography Guided Laser In Situ Keratomileusis
      (LASIK) corneal surgery to Small Incision Lenticule Extraction (SMILE) corneal surgery for
      the treatment of myopia with astigmatism.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of eyes with manifest refraction cylinder less than or equal to 0.5 diopter (D) at 3 months</measure>
    <time_frame>Month 3</time_frame>
    <description>Manifest refraction cylinder will be measured monocularly (each eye separately) with best correction under photopic lighting conditions using a 100% contrast ETDRS chart.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean manifest refraction cylinder at 3 months</measure>
    <time_frame>Month 3</time_frame>
    <description>Manifest refraction cylinder will be measured monocularly with best correction under photopic lighting conditions using a 100% contrast ETDRS chart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Uncorrected Visual Acuity (UCVA) at 3 months</measure>
    <time_frame>Month 3</time_frame>
    <description>Measurement of uncorrected (without spectacles or other visual corrective devices) visual acuity at both near and distance. Visual Acuity (VA) is measured in &quot;logarithm of the minimum angle of resolution&quot; (logMAR). A lower logMAR value indicates better visual acuity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Myopia</condition>
  <condition>Astigmatism</condition>
  <arm_group>
    <arm_group_label>LASIK with EX500</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topography Guided LASIK with WaveLight EX500 excimer laser system in bilateral surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SMILE with VisuMax</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Small incision lenticular extraction (SMILE) with VisuMax laser in bilateral surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Topography Guided LASIK</intervention_name>
    <description>Corneal surgery for refractive error correction</description>
    <arm_group_label>LASIK with EX500</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Small Incision Lenticular Extraction</intervention_name>
    <description>Refractive surgical procedure for the correction of myopia with or without astigmatism</description>
    <arm_group_label>SMILE with VisuMax</arm_group_label>
    <other_name>SMILE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>WaveLight EX500 Excimer Laser System</intervention_name>
    <description>As used for corneal stroma ablation (refractive error correction). The treatment is intended to last the subject's lifetime.</description>
    <arm_group_label>LASIK with EX500</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VisuMax Surgical Laser</intervention_name>
    <description>As used for lenticule creation/removal (refractive error correction). The treatment is intended to last the subject's lifetime.</description>
    <arm_group_label>SMILE with VisuMax</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to comprehend and sign an informed consent form;

          -  Willing and able to complete all postoperative visits;

          -  Myopia requiring refractive error correction of -0.5 to -8.0 D cylinder and at least
             0.75 D of corneal astigmatism;

          -  Intended treatment targeted for emmetropia;

          -  Preoperative best-corrected visual acuity (BCVA) of 0 logarithm minimum angle of
             refraction (logMAR);

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Pregnant or lactating, current or planned, during the course of the study;

          -  Dry eye;

          -  Corneal disease;

          -  Diagnosis of advanced glaucoma;

          -  Uncontrolled diabetes;

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Project Manager PLS</last_name>
    <role>Study Director</role>
    <affiliation>Alcon, A Novartis Division</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alcon Call Center</last_name>
    <phone>1-888-451-3937</phone>
    <email>alcon.medinfo@alcon.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75007</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 17, 2017</lastchanged_date>
  <firstreceived_date>December 7, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Astigmatism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
